Halozyme Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence.
HALO Key Statistics
Stock Snapshot
With a market cap of 8.38B, Halozyme Therapeutics(HALO) trades at $70.98. The stock has a price-to-earnings ratio of 27.75.
On 2026-02-21, Halozyme Therapeutics(HALO) stock traded between a low of $70.56 and a high of $72.72. Shares are currently priced at $70.98, which is +0.6% above the low and -2.4% below the high.
Halozyme Therapeutics(HALO) shares are trading with a volume of 2.01M, against a daily average of 2.44M.
During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $82.22 at its peak.
During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $82.22 at its peak.
HALO News
Halozyme Therapeutics ((HALO)) has held its Q4 earnings call. Read on for the main highlights of the call. President's Day Sale - 70% Off Unlock hedge fund-leve...
Image source: The Motley Fool. Feb. 17, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Helen I. Torley Chief Scientific Officer — Chris Wall...
Reports Q4 revenue $451.8M, consensus $446.14M. “2025 was a pivotal year for Halozyme (HALO) as we delivered record total revenue of $1.4B, which was the result...